NCT04655976

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 758 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

Conditions

• Lung Cancer, Non-Small Cell

Interventions

Type	Name	Description
BIOLOGICAL	Cobolimab	Cobolimab will be administered.
BIOLOGICAL	Dostarlimab	Dostarlimab will be administered.
DRUG	Docetaxel	Docetaxel will be administered.

Timeline

• Start date: 2020-12-08
• Primary completion: 2025-06-05
• Completion: 2027-03-30
• First posted: 2020-12-07
• Last updated: 2025-09-26

Locations

163 sites across 24 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Finland, France, Germany, Greece, Italy, Japan, Mexico, Netherlands, Poland, Romania, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study